The post TRX Price Prediction: Targeting $0.32-$0.35 by February as Analysts Eye Breakout appeared on BitcoinEthereumNews.com. Timothy Morano Jan 22, 2026 16The post TRX Price Prediction: Targeting $0.32-$0.35 by February as Analysts Eye Breakout appeared on BitcoinEthereumNews.com. Timothy Morano Jan 22, 2026 16

TRX Price Prediction: Targeting $0.32-$0.35 by February as Analysts Eye Breakout



Timothy Morano
Jan 22, 2026 16:12

TRX shows neutral momentum at $0.30 with analysts forecasting $0.32-$0.35 targets within 30 days. Technical indicators suggest consolidation phase may precede upward movement. TRX Price Prediction…

TRX shows neutral momentum at $0.30 with analysts forecasting $0.32-$0.35 targets within 30 days. Technical indicators suggest consolidation phase may precede upward movement.

TRX Price Prediction Summary

• Short-term target (1 week): $0.31
• Medium-term forecast (1 month): $0.32-$0.35 range
• Bullish breakout level: $0.322
• Critical support: $0.29

What Crypto Analysts Are Saying About TRON

Recent analyst sentiment around TRON has turned cautiously optimistic, with several experts highlighting key technical levels that could drive the next price movement.

Peter Zhang noted on January 20, 2026: “TRON shows neutral-bullish signals with RSI at 64 and resistance at $0.32. Technical patterns suggest potential move to $0.32-$0.35 range within 30 days if key levels break.”

Building on this analysis, Joerg Hiller stated on January 21, 2026: “TRON (TRX) shows neutral momentum at $0.30 with bullish MACD signals. Technical analysis suggests potential targets of $0.32-$0.35 within 30 days if resistance breaks.”

The most ambitious TRON forecast comes from CMC AI, who observed: “TRX’s path hinges on maintaining stablecoin dominance while navigating regulation. Its $0.30-$0.32 consolidation (Jan 2026) mirrors Bitcoin’s 2019 accumulation – a breakout above $0.322 resistance could retest $0.40.”

TRX Technical Analysis Breakdown

TRON’s current technical setup presents a mixed but increasingly constructive picture. Trading at $0.30, TRX sits precisely at multiple key technical levels, suggesting a critical inflection point.

The RSI reading of 51.58 places TRON in neutral territory, providing room for upward movement without entering overbought conditions. This balanced momentum indicator suggests neither extreme buying nor selling pressure, which often precedes significant directional moves.

MACD indicators show interesting dynamics with the MACD line at 0.0045 matching the signal line, resulting in a histogram reading of 0.0000. While technically showing bearish momentum, this convergence often signals an impending directional change.

Bollinger Bands analysis reveals TRX positioned at 0.46 between the bands, with the upper band at $0.32 representing immediate resistance and the lower band at $0.29 providing downside support. The middle band aligns with the current price at $0.30, reinforcing this level’s significance.

Moving averages paint a picture of consolidation, with the 7-day SMA at $0.31 providing slight upward bias while longer-term averages cluster around current levels. The 200-day SMA at $0.31 suggests long-term support above current prices.

TRON Price Targets: Bull vs Bear Case

Bullish Scenario

The TRON forecast turns increasingly positive if TRX can break above the $0.322 resistance level identified by analysts. Technical confirmation would come from:

  • RSI pushing above 60 while maintaining momentum
  • MACD histogram turning positive with sustained buying pressure
  • Volume expansion beyond the current $66.8 million daily average

In this scenario, the initial target of $0.32-$0.35 becomes achievable within the next 30 days. A sustained break above $0.35 could open the path toward the more ambitious $0.40 target suggested by CMC AI’s analysis.

Bearish Scenario

The downside risk for this TRX price prediction centers around a failure to hold the $0.30 support level. Key warning signs would include:

  • RSI dropping below 45, indicating weakening momentum
  • MACD histogram deepening into negative territory
  • Volume declining during any price weakness

A break below $0.29 (the lower Bollinger Band) could trigger a deeper correction toward $0.27-$0.28, where longer-term support levels reside.

Should You Buy TRX? Entry Strategy

For traders considering TRON positions, the current technical setup offers several strategic entry points:

Conservative Entry: Wait for a pullback to $0.29 support with RSI approaching oversold levels. This provides better risk-reward with a tight stop-loss at $0.28.

Aggressive Entry: Current levels around $0.30 offer immediate exposure with stop-loss at $0.29. Target the $0.32-$0.35 range for profit-taking.

Breakout Strategy: Enter on confirmed break above $0.322 with volume confirmation. This strategy targets the higher end of analyst forecasts but requires strict risk management.

Position sizing should remain conservative given cryptocurrency volatility, with stop-losses mandatory for any strategy.

Conclusion

This TRX price prediction suggests TRON stands at a critical juncture, with analyst consensus pointing toward $0.32-$0.35 targets over the next 30 days. The convergence of technical indicators at current levels supports the view that a significant move is imminent.

While the immediate bias appears neutral to slightly bullish, the key catalyst will be TRX’s ability to break above the $0.322 resistance level. Success here could validate the more optimistic forecasts extending toward $0.40.

Investors should remember that all price predictions carry inherent risks, and cryptocurrency markets remain highly volatile. This analysis should be considered alongside broader market conditions and individual risk tolerance before making investment decisions.

Image source: Shutterstock

Source: https://blockchain.news/news/20260122-price-prediction-trx-targeting-032-035-by-february-as

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26